Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

K2M Group Launches 3D-printed CASCADIA Lateral Interbody System

Executive Summary

K2M Group’s CASCADIA incorporates 3D printing for its Lamellar Titanium Technology to allow for bony integration throughout the implant. Surgeons now have a new alternative to traditional PEEK and titanium cages for the 90,000 spinal lateral fusion procedures performed globally each year, a market estimated at $500 million.

You may also be interested in...



3D Printing: Will Personalized Medical Devices Be The Next Big Thing?

Medical device manufacturers have a growing interest in 3D printing, a technology that could upend the manufacturing and distribution of certain medical devices and expand the scope of personalized medicine – especially in orthopedics, where it's used for some models, implants, and surgical cutting guides. Despite uncertainties related to regulation, reimbursement, and scaling up, global 3D printing revenues for medical and dental applications reached an estimated $537.1 million in 2014.

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel